Cipla Limited (NSE:CIPLA)
1,503.30
-8.20 (-0.54%)
Nov 4, 2025, 3:29 PM IST
Cipla Revenue
Cipla had revenue of 74.47B INR in the quarter ending September 30, 2025, with 6.98% growth. This brings the company's revenue in the last twelve months to 279.66B, up 6.48% year-over-year. In the fiscal year ending March 31, 2025, Cipla had annual revenue of 272.67B with 6.78% growth.
Revenue (ttm)
279.66B
Revenue Growth
+6.48%
P/S Ratio
4.34
Revenue / Employee
9.23M
Employees
30,313
Market Cap
1.21T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Biocon | 157.71B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Cipla News
- 9 hours ago - Top stocks to watch today, November 4, 2025: Bharti Airtel, Titan, Cipla, IEX, Indus Towers, Hero Moto, Power Grid, and more - Business Upturn
- 1 day ago - Cipla to acquire 100% stake in Inzpera Healthsciences for Rs 110.65 crore - Business Upturn
- 4 days ago - Nifty 50 top losers today, October 31: Eternal, NTPC, Cipla, Max Healthcare, HDFC Life, HDFC Life and more - Business Upturn
- 4 days ago - Cipla Ltd (BOM:500087) Half Year 2026 Earnings Call Highlights: Record Revenue and Strategic US ... - GuruFocus
- 4 days ago - Cipla's leadership change: Achin Gupta to succeed Umang Vohra - The Times of India
- 4 days ago - Half Year 2026 Cipla Ltd Earnings Call Transcript - GuruFocus
- 5 days ago - Cipla names Achin Gupta as next MD & Global CEO; Umang Vohra to step down in 2026 - Business Upturn
- 5 days ago - Cipla CEO Umang Vohra says Q2 marks ‘highest-ever quarterly revenue’; highlights obesity launch, US traction and emerging markets push - Business Upturn